Literature DB >> 23978096

Chronic inflammatory diseases and the Acute Respiratory Distress Syndrome (ARDS).

Ana Fernandez-Bustamante, John E Repine1.   

Abstract

The Acute Respiratory Distress Syndrome (ARDS) is a highly fatal pro-inflammatory oxidative respiratory disease. Relatively recently, the modulating effects of chronic inflammatory processes on ARDS susceptibility have been recognized in a number of clinical studies. Herein, we briefly review some of the chronic conditions that have been reported to increase (cigarette smoking and alcohol abuse) or decrease (diabetes and obesity) susceptibility to ARDS. We also propose some potential pathways that may hold clues regarding the pathogenesis and/or therapy for ARDS.

Entities:  

Mesh:

Year:  2014        PMID: 23978096     DOI: 10.2174/13816128113199990561

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  5 in total

1.  Emodin ameliorates LPS-induced acute lung injury, involving the inactivation of NF-κB in mice.

Authors:  Min Xiao; Tao Zhu; Wei Zhang; Tao Wang; Yong-Chun Shen; Qiong-Fang Wan; Fu-Qiang Wen
Journal:  Int J Mol Sci       Date:  2014-10-24       Impact factor: 5.923

Review 2.  Perioperative lung protective ventilation in obese patients.

Authors:  Ana Fernandez-Bustamante; Soshi Hashimoto; Ary Serpa Neto; Pierre Moine; Marcos F Vidal Melo; John E Repine
Journal:  BMC Anesthesiol       Date:  2015-05-06       Impact factor: 2.217

3.  Laminarin protects against hydrogen peroxide-induced oxidative damage in MRC-5 cells possibly via regulating NRF2.

Authors:  Xue Liu; Huaman Liu; Yi Zhai; Yan Li; Xue Zhu; Wei Zhang
Journal:  PeerJ       Date:  2017-07-31       Impact factor: 2.984

4.  Protective mechanism of sulforaphane in Nrf2 and anti-lung injury in ARDS rabbits.

Authors:  Zongjian Sun; Zhiqiang Niu; Shuishui Wu; Shiqiang Shan
Journal:  Exp Ther Med       Date:  2018-04-05       Impact factor: 2.447

5.  Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors.

Authors:  Haiying Liu; Zhengyan Wang; Lijun Ren; Guiqin Zhang; Dan Zhao; Yanli Guo; Lijuan Wang; Hong Feng
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-28       Impact factor: 2.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.